Product logins

Find logins to all Clarivate products below.


Global Healthcare: What Lessons Can Developed and Emerging Healthcare Systems Learn from One Another?

Driven by changing demographics and increasing medical costs, both mature and emerging markets are adopting novel strategies to manage their domestic healthcare systems. A range of methods are being adopted across the globe in an effort to optimize healthcare and manage the increasing costs associated with aging populations (in the mature markets) and with growing expectations (in emerging markets). Examples include market-entry agreements, risk-sharing, and value-based pricing in many European markets, government-driven efforts to encourage knowledge transfer that will allow the creation of a biologics manufacturing industry in Latin America, and relaxing requirements for local clinical trials in Asia without risking patient safety. Separately, decisions that occur outside of government can still influence the national experience with healthcare such as in the United States, where consolidation of PBMs and their willingness to exert their power have led to increasing power to negotiate on price in a market largely untouched by the type of cost pressures experienced in other developed markets. For any healthcare system seeking to improve, examples such as these (and others) provide opportunities to leverage prior experience and avoid prior mistakes.

Related Market Assessment Reports

Report
Dry and Wet Age-Related Macular Degeneration | Special Topics | US | 2019
The development of biosimilar versions of Lucentis and Eylea is of high interest in the ophthalmology market given the high cost of these agents, the large patient population suffering from retinal…
Report
Postoperative Pain | Special Topics | US | 2020
Postoperative pain comprises one of the larger segments of the total market for acute pain therapies, and it has experienced substantial growth over the past decade due to the market uptake of…
Report
Immune Checkpoint Inhibitors – Special Topics – Special Topics: Trends and Market Dynamics
Immune checkpoint inhibitors have transformed many oncology settings since their entry into the marketplace just over a decade ago. They are continuing to advance into earlier lines of therapy,…
Report
Antibody-Drug Conjugates – Special Topics – Special Topics: Trends and Market Dynamics
Antibody-drug conjugates have solidified their position as valuable tools against cancer. The agents combine the selectivity of monoclonal antibodies with the potency of cytotoxic drugs. The…
Report
Alzheimer’s Disease – Special Topics – Special Topics: Caregiver Perspectives on Diagnostics and Leqembi in the Treatment of Alzheimer’s Disease (US)
Eisai / Biogen’s Leqembi (lecanemab) gained accelerated and full FDA approval in 2023 based on positive clinical and biomarker outcomes from the Phase 3 CLARITY-AD trial. With the U.S. CMS…